<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03412357</url>
  </required_header>
  <id_info>
    <org_study_id>PO2128</org_study_id>
    <nct_id>NCT03412357</nct_id>
  </id_info>
  <brief_title>MesoTRAP: A Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma.</brief_title>
  <acronym>MesoTRAP</acronym>
  <official_title>MesoTRAP: A Pilot Clinical Trial and Feasibility Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma Designed to Address Recruitment and Randomisation Uncertainties and Sample Size Requirements for a Phase III Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Papworth Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sheffield</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Papworth Hospital NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malignant pleural mesothelioma is a cancer, caused by asbestos, which currently affects 2500
      people in the UK each year. The main symptom is breathlessness caused by fluid building up in
      the space between the lung and the chest wall (pleural effusion). Treatment involves draining
      the fluid to allow the lung to re-expand (pleurodesis). However, sometimes tumour growth over
      the surface of the lung can prevent it from re-expanding. This 'trapped' lung results in
      fluid re-accumulation and repeated drainage which can lead to discomfort and multiple
      hospital visits.

      One approach to dealing with 'trapped' lung in mesothelioma is to insert a thin tube
      (Indwelling Pleural Catheter - IPC) into the space around the lung. The tube can stay in
      place for a long time allowing patients to drain off fluid at home.

      Another approach is a keyhole surgical operation (video-assisted thoracoscopic partial
      pleurectomy/decortication - VAT-PD) to remove as much tumour as possible from the lining of
      the lung to allow it to re-expand.

      While both approaches are currently offered in clinical practice, it is not known which of
      the two is most effective at relieving breathlessness. The only way to find out is to conduct
      a research trial comparing the two. The Investigators plan to do this, but first of all need
      to carry out a small pilot study to collect information necessary to help plan the full
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-centre, open-label, randomised controlled pilot clinical trial and
      feasibility study comparing video-assisted thoracoscopic partial pleurectomy/decortication
      (VAT-PD) with indwelling pleural catheter (IPC) in patients with trapped lung (TL) and
      pleural effusion due to malignant pleural mesothelioma (MPM), aimed at addressing recruitment
      and randomisation uncertainties as well as sample size requirements for a full phase III
      study. 38 patients will be randomised and allocated in a 1:1 ratio to either VAT-PD or IPC.

      The study will be undertaken at mesothelioma surgical centres with expertise in either IPC,
      VAT-PD or both procedures, together with their linked non-surgical referral hospitals (hub
      and spoke). Patients meeting all eligibility criteria will be informed about the study,
      provided with a patient information sheet and given at least 24 hours to consider
      participation.

      Following consent, patients will be randomised, baseline measurements will be taken and a
      procedure date will be arranged. Following the procedure follow-up visits at 6 weeks, 3, 6
      and 12 months post-randomisation are planned to coincide with clinical care visits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To measure the standard deviation of Visual Analogue Scale scores for breathlessness</measure>
    <time_frame>Daily from randomisation to 12 months</time_frame>
    <description>The Visual Analogue Scale (VAS) is a 100mm line for patients to record the severity of a their breathlessness where 0mm is &quot;No breathlessness at all&quot; and 100mm is &quot;Worst possible breathlessness&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure the standard deviation of Visual Analogue Scale scores for chest pain</measure>
    <time_frame>Daily from randomisation to 12 months</time_frame>
    <description>The Visual Analogue Scale (VAS) is a 100mm line for patients to record the severity of a their chest pain where 0mm is &quot;No pain at all&quot; and 100mm is &quot;Worst possible pain&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life measured using the EQ-5D-5L</measure>
    <time_frame>Baseline, intervention, 6 weeks, 3, 6 and 12 months post randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life measured using the EORTC QLQC30</measure>
    <time_frame>Baseline, intervention, 6 weeks, 3, 6 and 12 months post randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at 30 days and 12 months post randomisation</measure>
    <time_frame>30 days and 12 months post randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From randomisation to the end of study follow-up (expected to be 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The prevalence of trapped lung in patients with MPM</measure>
    <time_frame>From beginning to end of recruitment period (18 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of eligible patients in participating centres</measure>
    <time_frame>From beginning to end of recruitment period (18 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recruitment rate</measure>
    <time_frame>From beginning to end of recruitment period (18 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess completion of resource use data during follow-up using patients' routine data</measure>
    <time_frame>Baseline, intervention, 6 weeks, 3, 6 and 12 months post randomisation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Malignant Pleural Mesothelioma</condition>
  <condition>Trapped Lung</condition>
  <arm_group>
    <arm_group_label>pleurectomy/decortication</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>indwelling pleural catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pleurectomy/decortication</intervention_name>
    <description>VAT-PD is a type of &quot;keyhole surgery&quot; performed under general anaesthesia using a telescope and instruments put inside the chest. Through small incisions, or keyholes made between the ribs, the thoracic surgeon removes the hard rind of the tumour over the surface of the lung, thereby allowing the 'trapped' lung to fully expand again. Simultaneous removal of mesothelioma from the outer pleural membrane allows pleurodesis to occur.</description>
    <arm_group_label>pleurectomy/decortication</arm_group_label>
    <other_name>video-assisted thoracoscopic partial pleurectomy/decortication</other_name>
    <other_name>VAT-PD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>indwelling pleural catheter</intervention_name>
    <description>A soft silicone catheter (IPC) with a one-way valve at the end is inserted a few centimetres under the skin under local anaesthesia. The inside end of the catheter is inserted into the pleural space and the outside end is connected to a vacuum drainage bottle. The IPC permits regular fluid drainage.</description>
    <arm_group_label>indwelling pleural catheter</arm_group_label>
    <other_name>IPC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed MPM

          2. Trapped lung, defined as a 'clinically significant trapped lung requiring intervention
             in the opinion of the clinical team&quot;

          3. Pleural effusion present (following re-accumulation)

          4. Considered by the clinical team to be suitable and fit enough to undergo VAT-PD

          5. Community services or patient/carer able to drain IPC at least twice weekly

          6. Considered by the clinical team to be equally suitable for treatment with VAT-PD or
             IPC, and therefore eligible for treatment allocation by randomisation.

          7. Patient willing to receive either VAT-PD or IPC and attend the respective designated
             centre for their treatment

          8. Expected survival of at least 4 months, as assessed by managing clinician

          9. Age â‰¥ 18 years

         10. Able to provide informed consent

        Exclusion Criteria:

          1. Lung re-expands fully following pleural fluid drainage i.e. no entrapment

          2. Previous attempt at pleurodesis on ipsilateral side

          3. Evidence of active pleural infection

          4. IPC in situ for more than 28 days

          5. Current participation in an RCT or CTIMP

          6. Females: pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Rintoul, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Papworth Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carol Freeman</last_name>
    <phone>0044 1480 366321</phone>
    <email>carolfreeman@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claire Matthews</last_name>
    <phone>0044 1480 364788</phone>
    <email>claire.matthews5@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Blackpool Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nidal Bittar</last_name>
      <email>Mr.Bittar@bfwhospitals.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Bristol NHS Trust</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Maskell</last_name>
    </contact>
    <contact_backup>
      <last_name>nick.maskell@bristol.ac.uk</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB23 5EF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Rintoul</last_name>
      <phone>0044 1480 364342</phone>
      <email>robert.rintoul@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jurgen Herre</last_name>
      <email>Jurgen.Herre@addenbrookes.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Kirk</last_name>
    </contact>
    <contact_backup>
      <last_name>Alan.kirk@gjnh.scot.nhs.uk</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital and New Victoria Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Blyth</last_name>
      <email>kevin.blyth@ggc.scot.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelvin Lau</last_name>
      <email>kelvin.lau@bartshealth.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dio Stravoulis</last_name>
    </contact>
    <contact_backup>
      <last_name>dio.stravoulis@ouh.nhs.uk</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>North West Anglia NHS Foundation Trust</name>
      <address>
        <city>Peterborough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pasupathy Sivasothy</last_name>
    </contact>
    <contact_backup>
      <last_name>Pasupathy-Rajah.Sivasothy@pbh-tr.nhs.uk</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Lancashire Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Preston</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Munavvar</last_name>
      <email>Mohammed.Munavvar@lthtr.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Edwards</last_name>
      <email>John.Edwards@sth.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2017</study_first_submitted>
  <study_first_submitted_qc>January 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2018</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pleurectomy/decortication</keyword>
  <keyword>indwelling pleural catheter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

